Brian A Karolewski studies organ transplantation, with an emphasis on the body's immune response to transplanted organs. Specifically, he investigates the concept of transplant tolerance, which is when the recipient's immune system accepts the transplanted organ without the need for lifelong immunosuppressive drugs. His research highlights the differences between kidney and liver transplants, examining whether specific conditioning techniques can promote organ acceptance without ongoing treatment, particularly in nonhuman primates.
Key findings
Attempting to induce liver transplant tolerance through transient-mixed chimerism in nonhuman primates was unsuccessful, indicating that different strategies are needed compared to kidney transplants.
This research confirms that previous successes in kidney transplant tolerance do not apply to liver transplants and require distinct approaches.
Frequently asked questions
Does Dr. Karolewski study organ transplants?
Yes, he studies organ transplantation, with a focus on achieving transplant tolerance.
What specific organs does Dr. Karolewski focus on?
He primarily researches the differences in immune responses to kidney and liver transplants.
Is Dr. Karolewski's work relevant to liver transplant patients?
Yes, his research addresses challenges in achieving tolerance for liver transplants, which is crucial for improving patient outcomes.
Publications in plain English
Macrophage-specific therapy blocks the lung's mechanosensitive immune response to alveolar distension.
2025
JCI insight
Mthunzi L, Islam MN, Gusarova GA, Karolewski B, Bhattacharya S +1 more
Plain English This study examined how immune cells in the lungs respond to overinflation, which can worsen breathing problems during mechanical ventilation. The researchers found that while overinflation didn’t stretch these immune cells, it did increase calcium levels inside them, contributing to lung injury. By blocking this calcium response, they were able to prevent damage caused by mechanical ventilation, pointing to new potential treatments to protect patients’ lungs.
Who this helps: This benefits patients with respiratory failure who require mechanical ventilation.
Macrophage-specific lipid nanoparticle therapy blocks the lung's mechanosensitive immunity due to macrophage-epithelial interactions.
2024
bioRxiv : the preprint server for biology
Mthunzi L, Islam MN, Gusarova GA, Bhattacharya S, Karolewski B +1 more
Plain English This study looked at how the lung's immune response gets activated when the tiny air sacs (alveoli) are overstretched, which can complicate breathing treatments for people with low oxygen levels. Researchers found that when these sacs stretched, certain immune cells called macrophages became more active and released a substance that can contribute to lung damage. By blocking a specific protein in these immune cells, scientists were able to reduce the harmful reactions in mice, pointing to a potential new therapy to prevent lung injury caused by mechanical ventilation.
Who this helps: This benefits patients with respiratory failure who are on ventilation support.
Transient-mixed Chimerism With Nonmyeloablative Conditioning Does Not Induce Liver Allograft Tolerance in Nonhuman Primates.
2020
Transplantation
Chaudhry S, Kato Y, Weiner J, Alonso-Guallart P, Baker S +13 more
Plain English Transplant tolerance—where the recipient's immune system accepts a donor organ without lifelong drugs—has been achieved for kidneys in primates but not for livers. This study tested whether creating temporary mixed bone marrow chimerism could induce tolerance to a transplanted liver in nonhuman primates. It did not, suggesting liver tolerance requires a fundamentally different approach than kidney tolerance.
Using reduced personal protective equipment in an endemically infected mouse colony.
2014
Journal of the American Association for Laboratory Animal Science : JAALAS
Baker SW, Prestia KA, Karolewski B
Plain English This study looked at whether using less protective gear, or personal protective equipment (PPE), would still keep a colony of mice from spreading diseases. Researchers found that when they used a simplified PPE approach, the mice remained free of harmful viruses over a 12-week period. This is important because it shows that it's possible to save money on protective gear while still effectively preventing disease spread in these research settings.
Who this helps: This benefits researchers and technicians working in animal facilities.
Efficacy of enrofloxacin in a mouse model of sepsis.
2014
Journal of the American Association for Laboratory Animal Science : JAALAS
Slate AR, Bandyopadhyay S, Francis KP, Papich MG, Karolewski B +2 more
Plain English The study looked at how effective an antibiotic called enrofloxacin is for treating severe infections in mice. Researchers found that mice receiving enrofloxacin through injections had higher drug levels in their bloodstream and better survival rates—65% survived compared to only 25% in untreated mice. This matters because it suggests that injecting enrofloxacin is more effective than giving it through drinking water for serious infections.
Who this helps: This helps veterinarians treating infected mice and may inform similar antibiotic treatments in other animals.
Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing beta-glucuronidase.
2006
Molecular therapy : the journal of the American Society of Gene Therapy
Plain English Researchers studied a treatment for a genetic brain disease called mucopolysaccharidosis type VII (MPS VII) by using a virus (herpes simplex virus) to deliver a missing enzyme into mice. They found that a single injection of the virus into the brain made the enzyme levels normal in several areas, correcting harmful storage problems in brain cells. This is significant because it shows a potential way to treat similar diseases in humans by effectively spreading the needed enzyme throughout the brain.
Who this helps: This helps patients with lysosomal storage diseases and their families.
Genetic correction of the fetal brain increases the lifespan of mice with the severe multisystemic disease mucopolysaccharidosis type VII.
2006
Molecular therapy : the journal of the American Society of Gene Therapy
Karolewski BA, Wolfe JH
Plain English Researchers studied a genetic treatment for a severe disease in mice called mucopolysaccharidosis type VII. They injected a corrected gene into the fetal brain, which not only stopped brain damage but also increased the mice's lifespan significantly, with treated mice living much longer than untreated ones. This is important because it shows that correcting genetic issues in the brain early can help manage diseases affecting the entire body.
Who this helps: This helps patients with genetic diseases and their families.
Ornithonyssus bacoti infestation and elimination from a mouse colony.
2005
Contemporary topics in laboratory animal science
Cole JS, Sabol-Jones M, Karolewski B, Byford T
Plain English This study looked at a problem with tropical rat mites infesting a mouse colony, causing skin irritations for staff. Initially, the mites were reduced with cleaning, but they returned within two weeks. The infestation was finally eliminated by using treated cotton balls in the mouse cages and spraying the facility, leading to no mites being detected for over three years.
Who this helps: This benefits the staff and researchers working in animal facilities.
Stable gene delivery to CNS cells using lentiviral vectors.
2004
Methods in molecular biology (Clifton, N.J.)
Watson DJ, Karolewski BA, Wolfe JH
Plain English This study looked at how well a specific type of virus, called lentiviral vectors, can deliver genes to nerve cells in the brain and spinal cord. The researchers found that these vectors are particularly effective because they can target cells that aren't dividing, like neurons, and successfully introduce new genes for research and treatment purposes. This is important because it could lead to better ways to study brain diseases and develop effective therapies for conditions like Alzheimer's and Parkinson's.
Who this helps: Patients with neurodegenerative diseases and researchers working to find new treatments.
Comparison of transfection conditions for a lentivirus vector produced in large volumes.
2003
Human gene therapy
Karolewski BA, Watson DJ, Parente MK, Wolfe JH
Plain English This study looked at different methods to create lentivirus vectors, which are tools used in gene therapy. Researchers tested various materials and found that using specific chemicals and less DNA than usual led to better virus production. They combined these findings into a streamlined process that can produce large volumes of virus, which is important for developing treatments.
Who this helps: This benefits researchers and companies working on gene therapy.